Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.

Harmony Biosciences Holdings, Inc. HRMY D&A

D&A at other companies

Jazz PharmaceuticalsJAZZ

$172.3M+11.6%

AlkermesALKS

$11.68M—

Axsome TherapeuticsAXSM

$1.57M0.0%

XER

Xeris Biopharma Holdings, Inc.XERS

$2.71M0.0%

Segments

By segment

See full

Rare Neurological Diseases$5.97M0.0%

Other financials

Income statement

See full

Revenue$215.4M+16.6%

Gross profit$170.9M+11.9%

Operating income$37.3M-33.7%

Net income$32.5M-28.7%

EPS (diluted)$0.55-29.5%

Balance sheet

See full

Cash & equivalents$589.4M+20.5%

Total debt$164.6M-7.2%

Total equity$910.3M+26.3%

Total assets$1.3B+20.5%

Cash flow

See full

Operating cash flow$27.8M-18.3%

CapEx$107.0K-79.1%

Free cash flow$126.0M+67.9%

Valuation

See full

Market cap$1.99B-14.9%

Profitability

See full

Gross margin76.5%-1.8pp

Operating margin21.1%-5.1pp

Net margin16.2%-4.3pp

FCF margin40.1%+9.5pp

Returns & leverage

See full

Return on equity17.9%-6.9pp

Debt / equity0.2×-0.1×

Current ratio3.6×-0.1×

Questions, answered.

What does D&A mean?: Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.